Concepedia

Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor–Associated Bleeding: A Retrospective Study

H Andrew Wilsey, Abby M. Bailey, Aric Schadler, George A. Davis, Melissa Nestor, Komal Pandya

Journal of Intensive Care Medicine · 2020 · 24 citations · 14 references

DOI

Abstract

Our comparison addresses a gap in the literature surrounding optimal dosing and supports a similar efficacy profile between dosing low- versus high-dose treatment.

References

14

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Craig T. January, L. Samüel Wann, Hugh Calkins et al. · Journal of the American College of Cardiology · 2019 · 2.2K citations

, , +10

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

Stuart J. Connolly, Mark Crowther, John W. Eikelboom et al. · New England Journal of Medicine · 2019 · 920 citations · Full text

American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy

Daniel M. Witt, Robby Nieuwlaat, Nathan P. Clark et al. · Blood Advances · 2018 · 489 citations · Full text

Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study

Ammar Majeed, Anna Ågren, Margareta Holmström et al. · Blood · 2017 · 315 citations

Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate

Hamim Zahir, Karen Brown, Alexander G. Vandell et al. · Circulation · 2014 · 250 citations